Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd (SGRL) last reported results for the quarter ended Jun 2026, with sales of ₹14.36 crore and net profit of ₹1.12 crore. The stock last traded at ₹726, a market capitalisation of ₹931 crore, on a P/E of 60.3. Over the past 52 weeks the stock has ranged between ₹381 and ₹759. Figures are as of 6 Oct 2026 and are not real time.
Shree Ganesh Remedies Ltd share price and key metrics
- Current price
- ₹726
- Market cap
- ₹931 cr
- Stock P/E
- 60.3
- Book value
- ₹127
- ROE
- 10.8%
- ROCE
- 14.1%
- Dividend yield
- 0.00%
- 52w high / low
- 759/381
Metrics as of 6 Oct 2026. Not real time.
Track Shree Ganesh Remedies Ltd
Cruxal reads every Shree Ganesh Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Shree Ganesh Remedies Ltd growth and returns
- 10 Years
- %
- 5 Years
- 17%
- 3 Years
- %
- TTM
- -9%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- %
- TTM
- -29%
- 10 Years
- %
- 5 Years
- 15%
- 3 Years
- 12%
- 1 Year
- 32%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- Last Year
- 11%
Shree Ganesh Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹14.36 cr, down 41.8% from ₹24.67 cr a year earlier. Net profit was ₹1.12 cr, down 67.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 32.33 | 27.05 | 24.43 | 24.67 | 30.32 | 21.11 | 33.2 | 14.36 |
| Expenses | 21.02 | 17.14 | 14.55 | 17.37 | 20.7 | 14.38 | 21.82 | 11.01 |
| Operating profit | 11.31 | 9.91 | 9.88 | 7.3 | 9.62 | 6.73 | 11.38 | 3.35 |
| OPM % | 34.98% | 36.64% | 40.44% | 29.59% | 31.73% | 31.88% | 34.28% | 23.33% |
| Other income | 0.19 | 0.71 | 2.29 | 0.66 | 0.69 | 0.66 | 1.02 | 0.94 |
| Interest | 0.44 | 0.39 | 0.97 | 0.94 | 1.01 | 0.74 | 0.88 | 0.32 |
| Depreciation | 2.42 | 2.7 | 2.42 | 2.42 | 2.59 | 2.67 | 2.8 | 2.44 |
| Profit before tax | 8.64 | 7.53 | 8.78 | 4.6 | 6.71 | 3.98 | 8.72 | 1.53 |
| Tax % | 25.81% | 27.89% | 24.83% | 25.00% | 26.23% | 22.36% | 28.21% | 27.45% |
| Net profit | 6.41 | 5.42 | 6.59 | 3.45 | 4.96 | 3.09 | 6.27 | 1.12 |
| EPS (₹) | 4.99 | 4.22 | 5.13 | 2.69 | 3.86 | 2.41 | 4.88 | 0.87 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Shree Ganesh Remedies Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 35 | 64 | 49 | 126 | 109 | 109 | 99 |
| Operating profit | 9 | 13 | 14 | 42 | 39 | 35 | 31 |
| OPM % | 25% | 20% | 28% | 33% | 36% | 32% | 31% |
| Net profit | 6 | 10 | 10 | 28 | 23 | 18 | 15 |
| EPS (₹) | 4.88 | 8.18 | 7.62 | 21.96 | 17.97 | 13.83 | 12.02 |
TTM is the trailing twelve months to the most recent quarter.
Shree Ganesh Remedies Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 9 | 9 | 13 | 13 | 13 |
| Reserves | 25 | 33 | 109 | 132 | 150 |
| Borrowings | 1 | 4 | 36 | 38 | 31 |
| Other liabilities | 7 | 9 | 12 | 8 | 14 |
| Total liabilities | 41 | 55 | 171 | 192 | 208 |
| Fixed assets | 14 | 20 | 81 | 95 | 105 |
| CWIP | 0 | 0 | 17 | 9 | 13 |
| Investments | 4 | 3 | 5 | 18 | 13 |
| Other assets | 23 | 32 | 69 | 70 | 78 |
| Total assets | 41 | 55 | 171 | 192 | 208 |
As reported by the company. Total assets equal total liabilities by construction.
Shree Ganesh Remedies Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -5 | 5 | 3 | 30 | 31 | 24 |
| Cash from investing | -0 | -3 | -1 | -33 | -35 | -9 |
| Cash from financing | -0 | -0 | -1 | 10 | -1 | -12 |
| Net cash flow | -5 | 1 | 2 | 7 | -6 | 3 |
| Free cash flow | -5 | 5 | 3 | -1 | 7 | 7 |
| CFO / operating profit | -60% | 37% | 24% | 92% | 104% | 82% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Shree Ganesh Remedies Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 35% | — | 19% | 14% |
| Debtor days | 101 | 101 | 59 | 75 | 109 |
| Inventory days | 125 | 61 | 156 | 223 | 209 |
| Days payable | 75 | 43 | 51 | 61 | 82 |
| Cash conversion cycle | 151 | 119 | 164 | 238 | 236 |
| Working capital days | 145 | 103 | 89 | 111 | 128 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Shree Ganesh Remedies Ltd shareholding pattern
Promoters held 72.83% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.52%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.49% | 72.80% | 72.80% | 72.80% | 72.80% | 72.80% | 72.83% | 72.83% |
| FIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.52% |
| Public | 29.50% | 27.19% | 27.20% | 27.20% | 27.19% | 27.20% | 27.16% | 26.65% |
| No. of shareholders | 8,508 | 8,695 | 8,978 | 9,166 | 8,752 | 8,442 | 8,058 | 7,822 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Shree Ganesh Remedies Ltd corporate filings
- Compliances - Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Shree Ganesh Remedies Limited announces resignation of Company Secretary and appointment of new CS, effective October 2026Otherslow impact
Cruxal's analysis: Shree Ganesh Remedies Limited has disclosed a key management change with the resignation…
Read the full analysis - Intimation of Trading Window ClosureInsider Trading / SASTlow impact
- Shree Ganesh Remedies Limited announces successful conclusion of 31st Annual General Meeting and voting resultsAGM/EGMlow impact
Cruxal's analysis: Shree Ganesh Remedies Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Shree Ganesh Remedies Limited Concludes 31st Annual General Meeting; Focus on FY26 Financials and Board AppointmentsAGM/EGMlow impact
Cruxal's analysis: Shree Ganesh Remedies Limited has successfully concluded its 31st Annual General Meeting…
Read the full analysis - Shree Ganesh Remedies Ltd publishes notice for Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Shree Ganesh Remedies Ltd has completed the mandatory newspaper publication for its…
Read the full analysis - Shree Ganesh Remedies Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Shree Ganesh Remedies Ltd has filed its Annual Report for the financial year 2025-26…
Read the full analysis - Shree Ganesh Remedies Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Shree Ganesh Remedies Ltd has fulfilled its regulatory obligation under Regulation 30 of…
Read the full analysis - Shree Ganesh Remedies Limited Reports Weak Q1FY27 Results Amidst Geopolitical Headwinds and Contract TerminationCompany Updatehigh impact
Cruxal's analysis: Shree Ganesh Remedies Limited reported a challenging Q1FY27, with revenue from operations…
Read the full analysis - Shree Ganesh Remedies Ltd files routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Shree Ganesh Remedies Ltd has submitted a press release under Regulation 30 of the SEBI…
Read the full analysis - Shree Ganesh Remedies Limited reports significant decline in Q1 FY2027 financial performanceBoard Meetinghigh impact
Cruxal's analysis: Shree Ganesh Remedies Limited reported a sharp contraction in its Q1 FY2027 financial…
Read the full analysis - Shree Ganesh Remedies Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Shree Ganesh Remedies Limited has issued a formal notice under Regulation 29 of SEBI…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.